[1]Labandeira-Garcia JL, Rodríguez-Perez AI, Villar-Cheda B, et al. Rho kinase and dopaminergic degeneration a promising therapeutic target for Parkinson’s disease[J]. Neuroscientist, 2015, 21(6): 616-629.
[2]Yan J, Fu Q, Cheng L, et al. Inflammatory response in Parkinson’s disease[J]. Mol Med Rep, 2014, 10(5): 2223-2233.
[3]Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson’s disease[J]. Cell Mol Life Sci, 2013, 70(22): 4259-4273.
[4]Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions[J]. Amino Acids, 2013, 45(1): 25-39.
[5]Waschek JA. VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair[J]. Br J Pharmacol, 2013, 169(3): 512-523.
[6]Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates[M]. Sydney:Academic Press, 1985: 87-92.
[7]Wang XX,Fu WY, Zhuang WX, et al. Improvement of rat model of Parkinson’s disease by unilateral striatal two-point and two-spot injection with 6-hydroxydopamine[J]. Chinese Journal of Neuroanatomy, 2015, 31(2): 187-192. (in Chinese)
王晓晓,付文玉,庄文欣,等. 改良纹状体内两点注射6-OHDA法制备大鼠帕金森病模型[J]. 神经解剖学杂志,2015,31(2): 187-192.
[8]Myhre O, Utkilen H, Duale N, et al. Metal dyshomeostasis and inflammation in Alzheimer’s and Parkinson’s diseases: possible impact of environmental exposures[J]. Oxid Med Cell Longev, 2013, 2013: 726954.
[9]Richardson JR, Hossain MM. Microglial ion channels as potential targets for neuroprotection in Parkinson’s disease[J]. Neural Plast, 2013, 2013: 587418.
[10]Streit WJ, Conde JR, Fendfick SE, et al. Role of microglia in the central nervous system’s immune response[J]. Neurol Res, 2005, 27(7): 685-691.
[11]OuchiY, Yagi S, Yokokura M, et al. Neuroinflammation in the living brain of Parkinson’sdisease[J]. Parkinsonism Relat Disord, 2009, 15(Suppl 3): S200-S204.
[12]Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson’s disease[J]. Prog Neurobiol, 2009, 89(3): 277-287.
[13]Zhuang WX, Fu WY, Lü E, et al. Changes of microglia and astrocyte in substantia nigra of 6-OHDA model rats of Parkinson’sdisease[J]. Acta Anatomica Sinica, 2010, 41(3): 344-348.(in Chinese)
庄文欣,付文玉,吕娥,等. 帕金森病大鼠黑质小胶质细胞及星形胶质细胞的变化[J]. 解剖学报,2010, 41(3): 344-348.
[14]Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: implications for translational research[J]. Trends Pharmacol Sci, 2009, 30(4): 174-181.
[15]Saijo K, Crotti A, Glass CK. Regulation of microglia activation and deactivation by nuclear receptors[J]. Glia, 2013, 61(1): 104-111.
[16]Peterson LJ, Flood PM. Oxidative stress and microglial cells in Parkinson’s disease[J]. Mediators Inflamm, 2012, 2012: 401264.
[17]Korkmaz OT, Tuncel N, Tuncel M, et al. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells[J]. J Mol Neurosci, 2010, 41(2): 278-287.
[18]Bensinger SJ, Tontonoz P. A Nurr1 pathway for neuroprotection[J]. Cell, 2009, 137(1): 26-28. |